US12005041B2 - Misoprostol dispersible tablet - Google Patents
Misoprostol dispersible tablet Download PDFInfo
- Publication number
- US12005041B2 US12005041B2 US17/861,711 US202217861711A US12005041B2 US 12005041 B2 US12005041 B2 US 12005041B2 US 202217861711 A US202217861711 A US 202217861711A US 12005041 B2 US12005041 B2 US 12005041B2
- Authority
- US
- United States
- Prior art keywords
- tablet
- misoprostol
- pharmaceutical
- water
- dispersion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 title claims abstract description 56
- 229960005249 misoprostol Drugs 0.000 title claims abstract description 56
- 239000007919 dispersible tablet Substances 0.000 title abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 230000006698 induction Effects 0.000 claims abstract description 17
- 230000005070 ripening Effects 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 51
- 239000006185 dispersion Substances 0.000 claims description 34
- 229920002472 Starch Polymers 0.000 claims description 21
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 20
- 235000019698 starch Nutrition 0.000 claims description 20
- 239000008107 starch Substances 0.000 claims description 19
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 18
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 17
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 229920002261 Corn starch Polymers 0.000 claims description 13
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 13
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
- 229960000913 crospovidone Drugs 0.000 claims description 12
- 235000019759 Maize starch Nutrition 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 238000013265 extended release Methods 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 239000011521 glass Substances 0.000 claims description 7
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 4
- 229920006037 cross link polymer Polymers 0.000 claims description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 4
- 238000007654 immersion Methods 0.000 claims description 3
- 239000012736 aqueous medium Substances 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 3
- 239000003826 tablet Substances 0.000 abstract description 97
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 64
- 239000007787 solid Substances 0.000 abstract description 5
- 206010036246 Post abortion haemorrhage Diseases 0.000 abstract 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 33
- 239000007884 disintegrant Substances 0.000 description 29
- OJLOPKGSLYJEMD-LNQMSSPSSA-N Cyotec Chemical compound CCCCC(C)(O)CC=C[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-LNQMSSPSSA-N 0.000 description 25
- 229940099378 cytotec Drugs 0.000 description 25
- 238000000034 method Methods 0.000 description 16
- 229940032147 starch Drugs 0.000 description 15
- 239000003085 diluting agent Substances 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 230000008961 swelling Effects 0.000 description 11
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 10
- 235000010980 cellulose Nutrition 0.000 description 10
- 229920002678 cellulose Polymers 0.000 description 10
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 10
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 10
- 239000002245 particle Substances 0.000 description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 9
- 239000001913 cellulose Substances 0.000 description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 8
- 239000000314 lubricant Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000012384 transportation and delivery Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000003 vaginal tablet Substances 0.000 description 6
- 229920000881 Modified starch Polymers 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229920003109 sodium starch glycolate Polymers 0.000 description 5
- 239000008109 sodium starch glycolate Substances 0.000 description 5
- 229940079832 sodium starch glycolate Drugs 0.000 description 5
- 208000034423 Delivery Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 235000019426 modified starch Nutrition 0.000 description 4
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- 230000009677 vaginal delivery Effects 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 240000003183 Manihot esculenta Species 0.000 description 3
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 3
- 239000004368 Modified starch Substances 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940044977 vaginal tablet Drugs 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 229920003086 cellulose ether Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000007580 dry-mixing Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- -1 glidants Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940079522 misoprostol 0.2 mg Drugs 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000008252 pharmaceutical gel Substances 0.000 description 2
- NFBAXHOPROOJAW-UHFFFAOYSA-N phenindione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C1=CC=CC=C1 NFBAXHOPROOJAW-UHFFFAOYSA-N 0.000 description 2
- 229960000280 phenindione Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000002522 swelling effect Effects 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 244000298643 Cassia fistula Species 0.000 description 1
- 235000007631 Cassia fistula Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229920003085 Kollidon® CL Polymers 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 241001127637 Plantago Species 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241000790234 Sphingomonas elodea Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 241000589636 Xanthomonas campestris Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 229920001586 anionic polysaccharide Polymers 0.000 description 1
- 150000004836 anionic polysaccharides Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000004955 epithelial membrane Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-N methyl hydrogen carbonate Chemical compound COC(O)=O CXHHBNMLPJOKQD-UHFFFAOYSA-N 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000008104 plant cellulose Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011591 potassium Chemical class 0.000 description 1
- 229910052700 potassium Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Definitions
- the present invention relates to a solid pharmaceutical formulation comprising misoprostol or a pharmaceutically acceptable salt thereof.
- the invention relates to a dispersible tablet comprising misoprostol or a pharmaceutically acceptable salt thereof.
- Prostaglandins have been associated with the onset of labor in women.
- Naturally occurring PGs are potent stimulants of human uterine contractility at any stage of pregnancy and also cause cervical ripening.
- Induction of labor is defined as the process of artificially stimulating the uterus to start labor. It may be performed by administering oxytocin or prostaglandins to the pregnant woman. Labor induction is one of the most frequent procedures in pregnant women.
- misoprostol products which comprise an extended release agent, hydrogenated castor oil.
- the International patent application WO 2006/133048 A2 relates to a controlled release pharmaceutical gel for vaginal administration, the pharmaceutical gel comprising misoprostol, a cellulose derivative and a polyol, wherein the gel is a substantially nonaqueous gel which forms a hydrogel when placed in a vaginal tract.
- the International patent application WO 2014/016394 A1 relates to the use of misoprostol for the induction of labor in a pregnant female, and in particular to the use of a sustained delivery device or insert containing 200 ⁇ g misoprostol for intravaginal use.
- vaginal tablets comprising misoprostol.
- the disclosed tablets comprise 100 ⁇ g misoprostol.
- a purported immediate release vaginal tablet and a sustained release vaginal tablet are disclosed, wherein the purported immediate release vaginal tablet are described as adhering to a tilted glass plate when placed on drops of water.
- Embodiments of the tablets are purported to adhere to an epithelial membrane.
- the vaginal tablets comprise lactose monohydrate, hydroxypropyl methylcellulose, corn starch and magnesium stearate.
- the vaginal tablets are manufactured by method steps comprising wet granulation, followed by drying in a fluid bed.
- the disclosed indications comprise cervical ripening and uterine contractions but not human labor.
- misoprostol formulations for labor induction comprises at least one extended release agents and/or is intended for sustained delivery.
- existing misoprostol products for vaginal use comprise an extended release agent, such as hydrogenated castor oil, and/or are supposed to adhere to the vaginal tract of a subject.
- misoprostol product which may provide a consistent dose irrespective of the route of administration, such as vaginal, oral or sublingual.
- misoprostol product which is developed for both sublingual and oral administration, as guidelines on a national level as well as at the level of the individual hospital may suggest use of misoprostol through either route of administration.
- the present invention concerns a pharmaceutical composition
- a pharmaceutical composition comprising misoprostol or a pharmaceutically acceptable salt thereof, allowing an administration form selected among sublingual, oral and vaginal administration.
- the invention concerns a method for obtaining cervical ripening or the induction of labor comprising administration of a pharmaceutical composition according to the invention.
- the pharmaceutical formulation is used for female human subjects.
- the invention concerns a method for the manufacture of a pharmaceutical composition of the invention, wherein said pharmaceutical composition is a tablet and said method comprises a step of compression.
- FIG. 1 is a flow chart showing the manufacturing process for a misoprostol tablet of the present invention.
- FIG. 2 A shows misoprostol tablets before being subjected to a disintegration experiment.
- Tablet A is on the left side
- Cytotec (a prior art misoprostol preparation) is on the right side.
- FIG. 2 B shows the tablets of FIG. 2 A at 3 seconds after being placed in beakers with a few drops of water.
- FIG. 2 C shows the tablets of FIG. 2 A at 7 seconds after being placed in beakers with a few drops of water.
- FIG. 2 D shows the tablets of FIG. 2 A at 15 seconds after being placed in beakers with a few drops of water.
- FIG. 3 A shows precipitate from Mixture I remaining on screens #20, #30, #40, #60, #80, and #100 as described in Example 5.
- FIG. 3 B shows precipitate from Mixture II remaining on screens #20, #30, #40, #60, #80, and #100 as described in Example 5.
- the present invention concerns a pharmaceutical composition
- a pharmaceutical composition comprising misoprostol or a pharmaceutically acceptable salt thereof, allowing an administration form selected among buccal, sublingual, oral and vaginal administration.
- the present invention concerns the pharmaceutical composition, wherein said pharmaceutical composition allows sublingual administration.
- Sublingual administration provided a larger peak in plasma concentration of misoprostol than oral and vaginal
- oral administration provided a larger peak than vaginal administration.
- Sublingual administration would appear to offer faster effective administration of misoprostol. This is likely to provide better efficacy and fewer side effects, as adjusting the dosage becomes easier.
- the present invention concerns the pharmaceutical composition, wherein said pharmaceutical composition allows any administration form selected among sublingual and oral administration.
- the present invention concerns the pharmaceutical composition, wherein said pharmaceutical composition allows any administration form selected among sublingual, oral and vaginal administration.
- Misoprostol product of the prior art are designed to be placed in the vagina for a longer time period, inherently carrying the risk of falling out. Due to the requirement of the present composition of a very small amount of liquid, it appears to be suitable for a vaginal environment.
- the present invention concerns the pharmaceutical composition, comprising a disintegrant comprising cross-linked PVP, preferably crospovidone.
- the disintegrant is a superdisintegrant.
- the cross-linked form of PVP is used as a disintegrant in pharmaceutical tablets.
- Polyvinylpolypyrrolidone polyvinyl polypyrrolidone, PVPP, crospovidone, crospolividone or E1202
- PVPP polyvinyl polypyrrolidone
- crospovidone polyvinyl polypyrrolidone
- crospolividone polyvinylpyrrolidone
- E1202 polyvinylpyrrolidone
- Crospovidone may provide rapid disintegration in the mouth, and is particularly preferred for a pharmaceutical composition of the invention for buccal or sublingual administration.
- Disintegrating agents are substances routinely included in the tablet formulations to aid in the break up of the compacted mass when it is put into a fluid environment. They promote moisture penetration and dispersion of the tablet matrix.
- Superdisintegrants several newer disintegrants have been developed known as “Superdisintegrants”. These newer substances are more effective at lower concentrations with greater disintegrating efficiency and mechanical strength. On contact with water the superdisintegrants swell, hydrate, change volume or form and produce a disruptive change in the tablet. Effective superdisintegrants provide improved compressibility, compatibility and have little negative impact on the mechanical strength of formulations. Commonly available superdisintegrants along with their commercial trade names are briefly described herewith.
- Modified starches Sodium starch glycolate which is the sodium salt of a carboxymethyl ether of starch. It is usually effective at a concentration of 2-8%. It can take up more than 20 times its weight in water and the resulting high swelling capacity combined with rapid uptake of water accounts for its high disintegration rate and efficiency. It is available in various grades i.e. Type A, B and C, which differ in pH, viscosity and sodium content.
- Modified celluloses, Carboxymethylcellulose and its derivative Cross-linked sodium carboxymethylcellulose is a white, free flowing powder with high absorption capacity. It has a high swelling capacity and thus provides rapid disintegration and drug dissolution at lower levels. It also has an outstanding water wicking capability and its cross-linked chemical structure creates an insoluble hydrophilic, highly absorbent material resulting in excellent swelling properties. Its usual recommended concentration is 0.5-2.0%, which can be used up to 5.0% L-HPC (Low substituted Hydroxy propyl cellulose). It is insoluble in water, swells rapidly and is usually used in the range of 1-5%. The grades LH-11 and LH-21 exhibit the greatest degree of swelling.
- Cross-linked sodium carboxymethylcellulose is a white, free flowing powder with high absorption capacity. It has a high swelling capacity and thus provides rapid disintegration and drug dissolution at lower levels. It also has an outstanding water wicking capability and its cross-linked chemical structure creates an insoluble hydrophilic, highly absorbent material resulting in excellent swelling properties. It
- Cross-linked polyvinylpyrrolidone is a completely water insoluble polymer. It rapidly disperses and swells in water but does not gel even after prolonged exposure. The rate of swelling is highest among all the superdisintegrants and is usually effective at 1-3%. It acts by wicking, swelling and possibly some deformation recovery.
- the polymer has a small particle size distribution that imparts a smooth mouth feel to dissolve quickly.
- Soy polysaccharide is a natural super disintegrant that does not contain any starch or sugar so can be used in nutritional products.
- Cross-linked alginic acid is insoluble in water and disintegrates by swelling or wicking action. It is a hydrophilic colloidal substance, which has high sorption capacity. It is also available as salts of sodium and potassium.
- Gellan gum is an anionic polysaccharide of linear tetrasaccharides, derived from Pseudomonas elodea having good superdisintegrant property similar to the modified starch and celluloses.
- Xanthan Gum derived from Xanthomonas campestris is official in the USP with high hydrophilicity and low gelling tendency.
- Calcium Silicate It is a highly porous, lightweight superdisintegrant, which acts by wicking action. Ion exchange resins The INDION 414 has been used as a superdisintegrant.
- Superdisintegrants such as natural or synthetic superdisintegrants, may be used for the present pharmaceutical compositions.
- Natural superdisintegrants used in formulations comprise, but are not limited to the group consisting of: Cassia fistula gum, LepidumSativum, Locust Bean gum, Plantago ovate Mucilage, Seed powder, Plantago ovata Husk powder, and Treated Agar.
- Synthetic Superdisintegrants used in formulations comprise, but are not limited to the group consisting of: crospovidone, Sodium Starch glycolate, Croscarmellose sodium (Ac-Di-Sol), kollidon CL, B-cyclodextrin, and Citric Acid and Sodium bicarbonate.
- the present invention concerns the pharmaceutical composition, comprising at least two disintegrants.
- the present invention concerns the pharmaceutical composition, wherein at least one of said at least two disintegrants is a cross-linked carboxymethylcellulose, preferably croscarmellose sodium.
- a suitable disintegrant is a modified cellulose, preferably a modified carboxymethylcellulose, more preferred a crosslinked polymer of carboxymethylcellulose, preferably croscarmellose.
- Croscarmellose sodium is an internally cross-linked sodium carboxymethylcellulose for use as a superdisintegrant in pharmaceutical formulations.
- the cross-linking reduces water solubility while still allowing the material to swell (like a sponge) and absorb many times its weight in water. As a result, it provides superior drug dissolution and disintegration characteristics, thus improving formulas subsequent bioavailability by bringing the active ingredients into better contact with bodily fluids.
- the present invention concerns the pharmaceutical composition, wherein said at least two disintegrants uses different mechanisms of disintegration.
- the expression “different mechanisms” also covers the case of partly overlap between the different mechanisms.
- Disintegrants may be classified by mechanism of disintegration as noted below.
- Disintegrants classified by mechanism of disintegration Mechanism of Examples of disintegration Method disintegrants I. Swelling The particles of the Croscarmellose sodium disintegrant swells when Starch hydrated. The swelling Polyplasdone XL 10 pressure destroys the interaction between the other particles. II. Porosity and Facilitate the movement of Croscarmellose sodium Capillary Action fluid into the tablet. Polyplasdone XL 10 (Wicking) III. Disintegrating Electric repulsive forces particle/Particle between particles arise repulsive forces when hydrated. IV. Deformation The compression of tablets Starch deform the particles, when Polyplasdone XL 10 in contact with water the particles return to their original size. V. Chemical Inside the tablet acid and reaction (Acid-Base base react and CO 2 is reaction) released creating a pressure that breaks the tablet apart. Highly sensitive to humidity and temperature. VI. Enzymatic Enzymes present in the Reaction body breaks down the binder of the tablet.
- the present invention concerns the pharmaceutical composition, wherein said at least two disintegrants uses mechanisms of disintegration comprising swelling, porosity and capillary action, and deformation.
- said at least two disintegrants uses mechanisms of disintegration comprising swelling, porosity and capillary action, and deformation.
- the mechanisms I. (swelling), II. (wicking) and IV. (deformation) are covered by said at least two disintegrants.
- the present invention concerns the pharmaceutical composition, wherein said at least two disintegrants are superdisintegrants.
- the present invention concerns the pharmaceutical composition
- a disintegrant which is starch, preferably maize starch.
- the present invention concerns the pharmaceutical composition, further comprising at least one superdisintegrant.
- the present invention concerns the pharmaceutical composition, wherein said pharmaceutical composition comprises an excipient selected among the group consisting of Maize starch (also known as Corn starch), Potato starch, Pea starch, Rice starch, Tapioca starch (also known as Cassava or Manioc starch), Wheat starch, and Modified starch.
- Maize starch also known as Corn starch
- Potato starch also known as Corn starch
- Pea starch also known as Corn starch
- Rice starch also known as Rice starch
- Tapioca starch also known as Cassava or Manioc starch
- Wheat starch and Modified starch.
- Potato starch was commonly used as a disintegrant. Recently, the use of so-called superdisintegrants such as crospovidone, croscarmellose sodium, and sodium starch glycolate have become more popular.
- Maize starch suffers from the drawback that tablets comprising maize starch tend to be hygroscopic and thus unstable. It has surprisingly been discovered that starch, in particular maize starch, is particularly preferred for solving the problems of the present invention. This is in particular true, if starch is combined with another disintegrant, preferably at least one superdisintegrant, more preferred at least two superdisintegrants.
- the present invention concerns the pharmaceutical composition, wherein said pharmaceutical composition comprises maize starch.
- the present invention concerns the pharmaceutical composition, wherein said pharmaceutical composition comprises an amount of disintegrant of 1-50%, preferably 2-30%, more preferred 3-25%, preferably 5-20%, more preferred 6-15%, preferably 8-12%, more preferred about 10%.
- the present invention concerns the pharmaceutical composition, wherein said pharmaceutical composition comprises an amount of superdisintegrant of 1-50%, preferably 2-30%, more preferred 3-25%, preferably 5-20%, more preferred 6-15%, preferably 8-12%, more preferred about 10%.
- the present invention concerns the pharmaceutical composition, wherein said pharmaceutical composition comprises an amount of croscarmellose sodium of 1-50%, preferably 2-30%, more preferred 3-25%, preferably 5-20%, more preferred 6-15%, preferably 8-12%, more preferred about 10%.
- the present invention concerns the pharmaceutical composition, wherein said pharmaceutical composition comprises an amount of crospovidone of 1-50%, preferably 2-30%, more preferred 3-25%, preferably 5-20%, more preferred 6-15%, preferably 8-12%, more preferred about 10%.
- the present invention concerns the pharmaceutical composition, wherein said pharmaceutical composition comprises an amount of starch of 1-50%, preferably 2-30%, more preferred 3-25%, preferably 5-20%, more preferred 6-15%, preferably 8-12%, more preferred about 10%.
- the present invention concerns the pharmaceutical composition, wherein said pharmaceutical composition comprises an amount of maize starch of 1-50%, preferably 2-30%, more preferred 3-25%, preferably 5-20%, more preferred 6-15%, preferably 8-12%, more preferred about 10%.
- the present invention concerns the pharmaceutical composition, wherein said pharmaceutical composition comprises an amount of microcrystalline cellulose of 1-99%, preferably 5-98%, more preferred 10-97%, preferably 20-95%, more preferred 30-90%, preferably 40-85%, more preferred 50-80%, preferably 60-75%, more preferred about 70%.
- the present invention concerns the pharmaceutical composition, wherein said pharmaceutical composition comprises an amount of flow agent of 0.1-10%, preferably 0.2-5%, more preferred 0.3-4%, preferably 0.5-3%, more preferred 0.8-2%, preferably about 1%.
- the present invention concerns the pharmaceutical composition, wherein said flow agent is colloidal silicon dioxide.
- the present invention concerns the pharmaceutical composition, having a content of misoprostol or a pharmaceutically acceptable salt thereof, selected among 0.5-1000, 1-500, 2.5-250, 5-100, 10-50, 20-30, and 25 ⁇ g.
- a pharmaceutically acceptable salt the amount is preferably equivalent to an amount of misoprostol selected among 0.5-1000, 1-500, 2.5-250, 5-100, 10-50, 20-30, and about 25 ⁇ g.
- the present invention concerns the pharmaceutical composition having a disintegration time of no more than 15 minutes, preferably less than 15 minutes, more preferred less than 10 minutes, preferably less than 5 minutes, more preferred less than 3 minutes, preferably less than 2 minutes, more preferred less than 1 minute, preferably less than 45 seconds, more preferred less than 30 seconds, preferably less than 25 seconds, more preferred less than 20 seconds, preferably less than 15 seconds, more preferred less than 10 seconds, preferably less than 9 seconds, more preferred less than 8 seconds, preferably less than 7 seconds, more preferred less than 6 seconds.
- the disintegration time is preferably measured using Disintegration apparatus A according to European Pharmacopoeia 8.0, placing one tablet in each of the 6 tubes of the basket without disc.
- the apparatus is operated using water medium as the immersion fluid, maintained at 37 ⁇ 2° C.
- Short disintegration time does not only allow sublingual administration, but surprisingly appears to allow vaginal administration without the need of an extended release agent and/or adherence to the vaginal tract.
- both sublingual and vaginal administration may be feasible.
- Fast dissolving drug delivery provides a number of advantages, comprising improved patient compliance, ease of swallowing, no water needed, and accuracy of dosage (Walid Habib, Raj Khankari, and John Hontz, “Fast-Dissolve Drug Delivery Systems”, Critical Reviews in Therapeutic Drug Carrier Systems, 17(1):61-72(2000)).
- the present invention concerns the pharmaceutical composition, wherein said disintegration time is measured initially after manufacture, preferably 3 months after manufacture, more preferred 6 months after manufacture, preferably 9 months after manufacture, more preferred 12 months after manufacture, preferably 18 months after manufacture, more preferred 24 months after manufacture.
- the present invention concerns the pharmaceutical composition, which allows dispersion of one or more of said pharmaceutical compositions in 100 ml water at 25° C. within 15 minutes, preferably within 10 minutes, more preferred within 5 minutes, preferably within 3 minutes, more preferred within 2 minutes, preferably within 1 minute, upon stirring, thereby providing a dispersion; said dispersion passing through a sieve screen with a nominal mesh aperture of 710 ⁇ m.
- the present invention concerns the pharmaceutical composition, which allows dispersion of one or more of said pharmaceutical compositions in 100 ml water at 25° C. within 15 minutes, preferably within 10 minutes, more preferred within 5 minutes, preferably within 3 minutes, more preferred within 2 minutes, preferably within 1 minute, substantially without stirring, thereby providing a dispersion; said dispersion passing through a sieve screen with a nominal mesh aperture of 710 ⁇ m.
- substantially without stirring means that the pharmaceutical composition provides a dispersion spontaneously upon contact with water without the need of stirring, shaking or other form of agitation, or stirring up to a speed of 1 RPM.
- the present invention concerns the pharmaceutical composition, which is a dispersible tablet.
- the present invention concerns the pharmaceutical composition, wherein said pharmaceutical composition is a tablet.
- the present invention concerns the pharmaceutical composition, further comprising a coating. While a preferred embodiment is a tablet without coating, another alternative is a tablet having a coating, e.g. to improve storage stability.
- the present invention concerns the pharmaceutical composition, further comprising at least one excipient, preferably selected among diluents, disintegrants, binders, glidants, lubricants, and coatings.
- excipient preferably selected among diluents, disintegrants, binders, glidants, lubricants, and coatings.
- An excipient is generally a pharmacologically inactive substance. Examples include, but are not limited to, diluents, disintegrants, binders, glidants, lubricants, and coatings. Other examples of suitable excipients may be found in Handbook of Pharmaceutical Excipients, 7 th Ed. by Rowe, Raymond C. et al., Pharmaceutical Press, London.
- Diluents are inactive ingredients that are added to tablets and capsules in addition to the active drug. Some very common diluents in tablets include starch, cellulose derivatives, and magnesium stearate (also a lubricant). Diluents fill out the size of a tablet or capsule, making it practical to produce and convenient for the consumer to use. By increasing the bulk volume, diluents make it possible for the final product to have the proper volume for patient handling. A good diluent must be inert, compatible with the other components of the formulation, non-hygroscopic, relatively cheap, compactable, and preferably tasteless or pleasant tasting. Plant cellulose (pure plant diluent) is a popular diluent in tablets or hard gelatin capsules.
- Dibasic calcium phosphate is another popular tablet diluent.
- a range of vegetable fats and oils can be used in soft gelatin capsules.
- Other examples of diluents include: lactose, sucrose, glucose, mannitol, sorbitol, calcium carbonate, and magnesium stearate.
- Disintegrants may expand and dissolve when wet causing the tablet to break apart. They ensure that when the tablet is in contact with water, it rapidly breaks down into smaller fragments, facilitating dissolution or dispersion.
- disintegrants include, but are not limited to: crosslinked polymers, such as crosslinked polyvinylpyrrolidone (crospovidone), and crosslinked sodium carboxymethyl cellulose (croscarmellose sodium); and the modified starch sodium starch glycolate. Specific examples further include Indion 414, L-HPC, and pregelatinised starch.
- Binders hold the ingredients in a tablet together. Binders ensure that tablets and granules can be formed with required mechanical strength, and give volume to tablets.
- binders include: saccharides and their derivatives: disaccharides, sucrose, lactose; polysaccharides and their derivatives, such as starches, cellulose or modified cellulose, such as microcrystalline cellulose and cellulose ethers such as hydroxypropyl cellulose (HPC); sugar alcohols such as xylitol, sorbitol or maltitol; further Protein: gelatin; and Synthetic polymers: polyvinylpyrrolidone (PVP), polyethylene glycol (PEG). Examples include gelatin, cellulose, cellulose derivatives, polyvinylpyrrolidone, starch, sucrose and polyethylene glycol. Other examples include cellulose, methyl cellulose, polyvinylpyrrolidone and polyethylene glycol.
- Glidants are used to promote powder flow by reducing interparticle friction and cohesion. These are used in combination with lubricants as they have no ability to reduce die wall friction. Examples include fumed silica, talc, and magnesium carbonate.
- Lubricants are agents added to tablet and capsule formulations to improve certain processing characteristics. Lubricants inter alia prevent ingredients from clumping together and from sticking to the tablet punches or capsule filling machine. Lubricants also ensure that tablet formation and ejection can occur with low friction between the solid and die wall. Common minerals like talc or silica, and fats, e.g. vegetable stearin, magnesium stearate or stearic acid are examples of lubricants used in tablets or hard gelatin capsules.
- Coatings protect ingredients from deterioration by moisture in the air and make large or unpleasant-tasting tablets easier to swallow.
- a cellulose ether hydroxypropyl methylcellulose (HPMC) film coating is used which is free of sugar and potential allergens.
- other coating materials are used, for example synthetic polymers, shellac, corn protein zein or other polysaccharides.
- a specific example is Opadry.
- Capsules are coated with gelatin.
- the present invention concerns the pharmaceutical composition, for cervical ripening or the induction of labor.
- the present invention concerns a method for obtaining cervical ripening or the induction of labor comprising administration of a pharmaceutical composition according to any of the preceding claims.
- a pharmaceutical composition according to any of the preceding claims.
- the pharmaceutical formulation is used for female human subjects.
- the present invention concerns the method, wherein 25 ⁇ g misoprostol, or an equivalent amount of pharmaceutically acceptable salt thereof, is administered orally or sublingually every 2-4 hours or vaginally every 6 hours.
- the present invention concerns the method, wherein 25 misoprostol, or an equivalent amount of pharmaceutically acceptable salt thereof, is administered orally or sublingually every 2-4 hours.
- the present invention concerns the method for the manufacture of a pharmaceutical composition, wherein said pharmaceutical composition is a tablet and said method comprises a step of compression.
- the present invention concerns the method, wherein said tablet is manufactured by a step of dry mixing followed by a step of direct compression.
- Example 1 Composition of the Invention
- FIG. 1 provides a flow chart of the manufacturing process.
- Step 1 Manually mix 75 g of Misoprostol (As 1 HPMC dispersion) with 75 g of Microcrystalline cellulose PH 112.
- Step 2 Mix 150 g of step 1 blend with 150 g of Microcrystalline cellulose PH 112.
- Step 3 Mix 300 g of step 2 blend with 300 g of Microcrystalline cellulose PH 112.
- Step 4 Mix 600 g of step 3 blend with 600 g of Microcrystalline cellulose PH 112.
- Load step 4 blend into the main bowl of planetary mixer and mix for 15 min.
- Compress in a compression machine (using 7.5 ⁇ 4.5 mm—punch).
- the disintegration time of tablets manufactured according to Example 1 were measured initially (right after manufacture) as well as after several months.
- the tablets were packed in Alu-Alu blister packs, maintained at 30 ⁇ 2° C. and 65 ⁇ 5% RH.
- the disintegration time was measured according to European Pharmacopoeia 8.0, using Disintegration apparatus A, placing one tablet in each of the 6 tubes of the basket without disc.
- the apparatus was operated using water medium as the immersion fluid, maintained at 37 ⁇ 0.5° C. After disintegration of the tablets the basket was lifted from the fluid, and all of the tablets had disintegrated completely.
- the measured disintegration times are provided in the table below.
- the tablets were found to have satisfactory disintegration time and stability.
- Tablet A a tablet manufactured according to Example 1 (“Tablet A”) was subjected to the test of Example 4 of WO 2007/035954. Tablet A was compared to a commercially available Cytotec misoprostol tablet.
- Tablet A Due to the short disintegration time, Tablet A will immediately form a dispersion upon contact with water or an aqueous medium. Therefore, Tablet A is not dependent on adherence to the vaginal tract upon administration.
- a tablet of the present invention was compared with a tablet of the prior art.
- a tablet manufactured according to Example 1 (“Tablet A”) was compared to a commercially available Cytotec misoprostol 0.2 mg tablet. Each tablet was placed in a beaker with a few drops of water. Photographs were recorded after 3, 7 and 15 seconds. Between each photograph, the beakers were very gently agitated by rotating the beakers.
- FIG. 2 A shows the tablets before being subjected to a disintegration experiment.
- Tablet A is on the left side
- Cytotec is on the right side.
- FIG. 2 B shows the tablets 3 seconds after being placed in beakers with a few drops of water.
- FIG. 2 C shows the tablets 7 seconds after being placed in beakers with a few drops of water.
- FIG. 2 D shows the tablets 15 seconds after being placed in beakers with a few drops of water.
- a dispersion is formed immediately after bringing Tablet A in contact with water.
- Cytotec no dispersion is formed, large flakes are formed, and the Cytotec tablet is not suitable for sublingual administration. Further, vaginal administration would require the Cytotec tablet to stay for a prolonged time in the vaginal tract.
- Tablets manufactured according to Example 1 (“Tablet A”), comprising 25 ⁇ g misoprostol, were compared to commercially available Cytotec tablets, comprising misoprostol 0.2 mg.
- Dispersibility test were performed using water at room temperature. Two tablets of Tablet A were mixed with 100 ml water (Mixture I), and two tablets of Cytotec were mixed with 100 ml (Mixture II) water in both cases while stirring for 180 seconds. For Tablet A, a dispersion forms within a few seconds. For Cytotec, no dispersion is formed, the tablets disintegrate slowly and a suspension is formed. Upon discontinuing stirring, the dispersion comprising Tablet A remains stable, while precipitate is clearly visible in the bottom of the suspension comprising Cytotec.
- the mixtures were poured through sieve screens #20, #30, #40, #60, #80, and #100, having apertures of 900 ⁇ m, 600 ⁇ m, 400 ⁇ m, 250 ⁇ m, 200 ⁇ m, and 140 ⁇ m.
- For Mixture II it was necessary to continue stirring until just before pouring, in order ensure substantially all of the mixture was poured into the sieve. This was not the case for Mixture I which had formed a stable dispersion.
- Tablet A is a dispersible tablet, while Cytotec is not a dispersible tablet.
- Example 6 Compositions of the Invention
- Tablet C A B 200 ⁇ g tablet 25 ⁇ g tablet 200 ⁇ g tablet w/o Maize starch (mg/tablet) (mg/tablet) (mg/tablet) Misoprostol 2.5 20 20 (as 1% HPMC dispersion) Microcrystalline cellulose 69.5 57 62 Maize starch 10 5 0 Croscarmellose sodium 10 10 10 Crospovidone 10 10 10 Colloidal anhydrous silica 1 1 1 Total (mg) 103 103 103 103 103
- Cytotec tablets contain 200 micrograms ( ⁇ g) of the active substance, misoprostol.
- the other ingredients are indicated to be: microcrystalline cellulose, sodium starch glycolate, hydrogenated castor oil, and hypromellose (E464).
- Cytotec tablets are white to off white hexagonal tablets scored on both sides. According to the package leaflet, the tablets may help prevent getting ulcers in the stomach or duodenum, and can also be used to heal existing ulcers. Patients are warned against using Cytotec if they are pregnant or trying to become pregnant, because it may cause a miscarriage according to the leaflet. According to the leaflet, patients should take two 200 microgram Cytotec tablets twice a day with food, or alternatively one Cytotec tablet four times a day, at regular intervals with food.
- Cytotec tablets containing 200 micrograms ( ⁇ g) misoprostol may be mixed with water to produce mixtures comprising solid residues.
- Solid tablets according to the invention (Tablet A) comprising 25 ⁇ g misoprostol were compared to 200 ⁇ g Cytotec tablets mixed with and diluted to 200 ml with water (CYTOTEC), of which either 25 or 50 ml was administered orally.
- the mixture CYTOTEC is presently used as off-label treatment in Sweden for labor induction.
- the dosage of 200 ⁇ g of the Cytotec tablets make them unsuitable for providing dosages of 25 or 50 ⁇ g without division of the tablet.
- the tablets have a hexagonal shape with one groove making it difficult to divide the tablets precisely in 1 ⁇ 8 or 1 ⁇ 4 fractions.
- the four (4) treatment groups comprise oral administration of 25 ⁇ g 2-hourly and 50 ⁇ g 4-hourly, comparing Tablet A and CYTOTEC for each administration dosage. Each group consisted of 12 women. The results are provided below.
- the symbol t 1/2 denotes the terminal half-life.
- Tablet A which is free from extended release agents because it is designed to be suitable for sublingual administration, provides a shorter t 1/2 compared to CYTOTEC.
- the active ingredient is immediately dispersed upon oral administration as a tablet, providing faster uptake of the active ingredient.
- CYTOTEC has longer t 1/2 due to the presence of an extended release agent.
- the extended release agent retards the uptake of the active ingredient, even if the Cytotec tablet is administered as a mixture with water.
- the active ingredient, misoprostol is intimately mixed with the extended release agent of Cytotec, providing a longer release time, resulting in longer t 1/2 and leading to longer duration of induction of delivery times.
- a more sudden increase (followed by decrease) of the concentration of misoprostol kick-starts processes provoking the shorter duration of induction to delivery times.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Disintegrants classified by mechanism of disintegration |
Mechanism of | Examples of | |
disintegration | Method | disintegrants |
I. Swelling | The particles of the | Croscarmellose sodium |
disintegrant swells when | Starch | |
hydrated. The swelling | Polyplasdone XL 10 | |
pressure destroys the | ||
interaction between the | ||
other particles. | ||
II. Porosity and | Facilitate the movement of | Croscarmellose sodium |
Capillary Action | fluid into the tablet. | Polyplasdone XL 10 |
(Wicking) | ||
III. Disintegrating | Electric repulsive forces | |
particle/Particle | between particles arise | |
repulsive forces | when hydrated. | |
IV. Deformation | The compression of tablets | Starch |
deform the particles, when | Polyplasdone XL 10 | |
in contact with water the | ||
particles return to their | ||
original size. | ||
V. Chemical | Inside the tablet acid and | |
reaction (Acid-Base | base react and CO2 is | |
reaction) | released creating a pressure | |
that breaks the tablet apart. | ||
Highly sensitive to humidity | ||
and temperature. | ||
VI. Enzymatic | Enzymes present in the | |
Reaction | body breaks down the | |
binder of the tablet. | ||
Ingredient | mg/Tablet | Ascribed function |
Misoprostol | 2.50 | API |
(as 1% HPMC dispersion) | ||
Microcrystalline Cellulose | 69.5 | Binder/Diluent/ |
(PH112) | disintegrant | |
Starch Plain (maize starch) | 10.0 | Diluent/disintegrant |
Croscarmellose Sodium | 10.0 | Super disintegrant |
(Ac-di-sol) | ||
Polyplasdone XL 10 | 10.0 | Super disintegrant |
(Crospovidone) | ||
Colloidal Silicon Dioxide | 1.00 | Improves flow properties |
103.0 | ||
Misoprostol (as 1% HPMC dispersion) provides 2.50 mg/100 = 25 μg misoprostol per tablet. |
3rd | 6th | 9th | 12th | 18th | ||
Initial | month | month | month | month | month | |
Disintegration | 4 | 5 | 5 | 5 | 6 | 5 |
time | seconds | seconds | seconds | seconds | seconds | seconds |
The tablets were found to have satisfactory disintegration time and stability. |
Tablet |
C | |||
A | B | 200 μg tablet | |
25 μg tablet | 200 μg tablet | w/o Maize starch | |
(mg/tablet) | (mg/tablet) | (mg/tablet) | |
Misoprostol | 2.5 | 20 | 20 |
(as 1% HPMC dispersion) | |||
Microcrystalline cellulose | 69.5 | 57 | 62 |
Maize starch | 10 | 5 | 0 |
Croscarmellose sodium | 10 | 10 | 10 |
Crospovidone | 10 | 10 | 10 |
Colloidal anhydrous silica | 1 | 1 | 1 |
Total (mg) | 103 | 103 | 103 |
50 μg 4-hourly |
Mean t1/2 (hrs) | Tablet A | 0.57 | |
CYTOTEC | 0.70 | ||
Vaginal delivery | Tablet A | 11 (of 12 women) | |
CYTOTEC | 5 (of 12 women) | ||
Duration (hrs) of | Tablet A | 20.5 | |
Induction to delivery | CYTOTEC | 27.5 |
25 μg 2-hourly |
Mean t1/2 (hrs) | Tablet A | 0.43 | ||
CYTOTEC | 0.60 | |||
Vaginal delivery | Tablet A | 9 (of 12 women) | ||
CYTOTEC | 11 (of 12 women) | |||
Duration (hrs) of | Tablet A | 17.9 | ||
Induction to delivery | CYTOTEC | 25.5 | ||
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/861,711 US12005041B2 (en) | 2014-07-11 | 2022-07-11 | Misoprostol dispersible tablet |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14176821.8A EP2965750B1 (en) | 2014-07-11 | 2014-07-11 | Misoprostol dispersible tablet |
EP14176821 | 2014-07-11 | ||
EP14176821.8 | 2014-07-11 | ||
US14/329,023 US20160008310A1 (en) | 2014-07-11 | 2014-07-11 | Misoprostol dispersible tablet |
PCT/DK2015/050216 WO2016004960A2 (en) | 2014-07-11 | 2015-07-10 | Misoprostol dispersible tablet |
US201715324395A | 2017-01-06 | 2017-01-06 | |
US16/870,556 US11406615B2 (en) | 2014-07-11 | 2020-05-08 | Misoprostol dispersible tablet |
US17/861,711 US12005041B2 (en) | 2014-07-11 | 2022-07-11 | Misoprostol dispersible tablet |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/870,556 Continuation US11406615B2 (en) | 2014-07-11 | 2020-05-08 | Misoprostol dispersible tablet |
Publications (2)
Publication Number | Publication Date |
---|---|
US20220347145A1 US20220347145A1 (en) | 2022-11-03 |
US12005041B2 true US12005041B2 (en) | 2024-06-11 |
Family
ID=53879283
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/870,556 Active US11406615B2 (en) | 2014-07-11 | 2020-05-08 | Misoprostol dispersible tablet |
US17/861,711 Active US12005041B2 (en) | 2014-07-11 | 2022-07-11 | Misoprostol dispersible tablet |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/870,556 Active US11406615B2 (en) | 2014-07-11 | 2020-05-08 | Misoprostol dispersible tablet |
Country Status (12)
Country | Link |
---|---|
US (2) | US11406615B2 (en) |
EP (1) | EP3166597A2 (en) |
JP (2) | JP6532529B2 (en) |
AU (1) | AU2015287186B2 (en) |
BR (1) | BR112017000529A2 (en) |
CA (1) | CA2954086C (en) |
EA (1) | EA039069B1 (en) |
MX (1) | MX2017000399A (en) |
NZ (1) | NZ727876A (en) |
RU (1) | RU2017104233A (en) |
TN (1) | TN2017000003A1 (en) |
WO (1) | WO2016004960A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108434110B (en) * | 2018-04-28 | 2019-09-10 | 浙江仙琚制药股份有限公司 | Misoprostol composition, tablet and application thereof |
Citations (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3197864A (en) | 1962-07-18 | 1965-08-03 | Needle Industries Ltd | Cutter members for dry shavers |
US4335097A (en) | 1981-01-15 | 1982-06-15 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Stabilized, prostaglandin-containing tablets with controlled rate of solubility, for local use and process for the preparation thereof |
EP0574185A2 (en) | 1992-06-08 | 1993-12-15 | Newpharma International Corporation | PGE1 analogs |
JPH06199779A (en) | 1992-06-08 | 1994-07-19 | Newpharma Internatl Corp | Methyl ester of trans-2-15-deoxy-16-hydroxy-16-methyl-pgei |
WO1996009825A1 (en) | 1994-09-27 | 1996-04-04 | University College London | Prostagladin analogues by the oral or vaginal route for the routine management of the third stage of labour |
US5993856A (en) | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
WO2001013836A1 (en) | 1999-08-26 | 2001-03-01 | West Virginia University | Cervical agent delivery system |
US6228213B1 (en) | 1997-09-19 | 2001-05-08 | University Of Nebraska-Lincoln | Production of microcrystalline cellulose by reactive extrusion |
WO2002092097A1 (en) | 2001-05-11 | 2002-11-21 | Medical Research Council | Composition comprising phosphodiesterase inhibitors for inducing cervical ripening |
WO2004000197A2 (en) | 2002-06-21 | 2003-12-31 | Biovail Laboratories Inc. | Quick dissolve compositions and tablets based thereon |
US20050100600A1 (en) | 1999-12-06 | 2005-05-12 | John Staniforth | Pharmaceutical superdisintegrant |
US20050169986A1 (en) | 2002-02-28 | 2005-08-04 | Wei Tian | Fast disintegrating tablets |
US20060115528A1 (en) | 2002-06-21 | 2006-06-01 | Vesna Skulj | Rapidly disintegrating tablet |
US20060228409A1 (en) | 2003-03-28 | 2006-10-12 | Kyowa Hakko Kogyo Co., Ltd. | Scored tablet |
WO2006125450A1 (en) | 2005-05-26 | 2006-11-30 | Atef Mohammed Mostafa Darwish | Rectal and vaginal suppositories containing misoprostol |
WO2006133048A2 (en) | 2005-06-03 | 2006-12-14 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same |
WO2007035954A2 (en) | 2005-09-23 | 2007-03-29 | Duramed Pharmaceuticals, Inc. | Vaginal tablets comprising misoprostol and methods of making and using the same |
CN1939308A (en) | 2005-09-28 | 2007-04-04 | 应圣俊 | Misoalprostacol suppository |
EP1987820A1 (en) | 2007-05-04 | 2008-11-05 | Christian Fiala, Ph. D. | Slow release misoprostol for obstetric and/or gynaecological applications |
US20080312168A1 (en) * | 2005-07-22 | 2008-12-18 | Rubicon Research Pvt. Ltd | Novel Dispersible Tablet Composition |
WO2009043844A2 (en) | 2007-10-01 | 2009-04-09 | Laboratorios Lesvi, S.L. | Orodispersible tablets |
WO2009154810A2 (en) | 2008-02-25 | 2009-12-23 | Dr. Reddy's Laboratories Ltd. | Delivery systems for multiple active agents |
WO2010036878A1 (en) | 2008-09-26 | 2010-04-01 | The Trustees Of Columbia University In The City Of New York | Use of trpv1 receptor agonists in cervical pain and labor |
RU2394814C1 (en) | 2009-05-22 | 2010-07-20 | Учреждение Российской академии наук Институт органической химии Уфимского научного центра РАН | Ethyl ether (±)-11,15-dideoxy-16-methyl-16-hydroxyprostaglandin e1 agent which exhibits uterotonic activity |
US20100260825A1 (en) | 2009-04-13 | 2010-10-14 | Nair Madhavan G | Antifolates for the treatment of cardiovascular, inflammatory, neoplastic, autoimmune and related diseases in sublingual dosage units, film strips, or skin patches |
WO2011156812A2 (en) | 2010-06-11 | 2011-12-15 | Controlled Therapeutics (Scotland) Ltd. | Intravaginal administration of misoprostol |
CN102302443A (en) | 2011-09-21 | 2012-01-04 | 天津市聚星康华医药科技有限公司 | Misoprostol vaginal sustained-release suppository and preparation method thereof |
US20120077888A1 (en) | 2009-03-26 | 2012-03-29 | Royal College Of Surgeons In Ireland | Orodispersible tablets |
CN102697746A (en) | 2012-06-11 | 2012-10-03 | 广州朗圣药业有限公司 | Rapid melting misoprostol vaginal composition as well as preparation method and application of same |
CN102872024A (en) | 2012-09-28 | 2013-01-16 | 天津市聚星康华医药科技有限公司 | Misoprostol medicine combination used in mouths |
CN103040842A (en) | 2012-12-08 | 2013-04-17 | 杭州圣诺医学科技有限公司 | Prostaglandin pharmaceutical composition and prostaglandin medicament suppository prepared by the prostaglandin pharmaceutical composition |
CN103340837A (en) | 2013-07-08 | 2013-10-09 | 天津市聚星康华医药科技有限公司 | Misoprostol vaginal effervescent tablets and preparation method thereof |
EP2689781A1 (en) | 2012-07-26 | 2014-01-29 | Ferring B.V. | Misoprostol composition |
EP2689802A1 (en) | 2012-07-26 | 2014-01-29 | Ferring B.V. | Misoprostol formulation |
WO2014016390A1 (en) | 2012-07-26 | 2014-01-30 | Ferring B.V. | Misoprostol formulation |
WO2014016394A1 (en) | 2012-07-26 | 2014-01-30 | Ferring B.V. | Misprostol composition |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7799530B2 (en) | 2005-09-23 | 2010-09-21 | Celera Corporation | Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof |
-
2015
- 2015-07-10 TN TN2017000003A patent/TN2017000003A1/en unknown
- 2015-07-10 AU AU2015287186A patent/AU2015287186B2/en active Active
- 2015-07-10 RU RU2017104233A patent/RU2017104233A/en not_active Application Discontinuation
- 2015-07-10 NZ NZ727876A patent/NZ727876A/en unknown
- 2015-07-10 BR BR112017000529A patent/BR112017000529A2/en not_active Application Discontinuation
- 2015-07-10 CA CA2954086A patent/CA2954086C/en active Active
- 2015-07-10 EP EP15750921.7A patent/EP3166597A2/en active Pending
- 2015-07-10 WO PCT/DK2015/050216 patent/WO2016004960A2/en active Application Filing
- 2015-07-10 MX MX2017000399A patent/MX2017000399A/en unknown
- 2015-07-10 JP JP2017521290A patent/JP6532529B2/en active Active
- 2015-07-10 EA EA201692536A patent/EA039069B1/en unknown
-
2019
- 2019-05-20 JP JP2019094296A patent/JP6921894B2/en active Active
-
2020
- 2020-05-08 US US16/870,556 patent/US11406615B2/en active Active
-
2022
- 2022-07-11 US US17/861,711 patent/US12005041B2/en active Active
Patent Citations (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3197864A (en) | 1962-07-18 | 1965-08-03 | Needle Industries Ltd | Cutter members for dry shavers |
US4335097A (en) | 1981-01-15 | 1982-06-15 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Stabilized, prostaglandin-containing tablets with controlled rate of solubility, for local use and process for the preparation thereof |
EP0574185A2 (en) | 1992-06-08 | 1993-12-15 | Newpharma International Corporation | PGE1 analogs |
JPH06199779A (en) | 1992-06-08 | 1994-07-19 | Newpharma Internatl Corp | Methyl ester of trans-2-15-deoxy-16-hydroxy-16-methyl-pgei |
WO1996009825A1 (en) | 1994-09-27 | 1996-04-04 | University College London | Prostagladin analogues by the oral or vaginal route for the routine management of the third stage of labour |
US6664290B1 (en) | 1994-09-27 | 2003-12-16 | University College London | Oral or vaginal administration of mesoprostol in third stage labor |
US5993856A (en) | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
US6228213B1 (en) | 1997-09-19 | 2001-05-08 | University Of Nebraska-Lincoln | Production of microcrystalline cellulose by reactive extrusion |
WO2001013836A1 (en) | 1999-08-26 | 2001-03-01 | West Virginia University | Cervical agent delivery system |
US20050100600A1 (en) | 1999-12-06 | 2005-05-12 | John Staniforth | Pharmaceutical superdisintegrant |
WO2002092097A1 (en) | 2001-05-11 | 2002-11-21 | Medical Research Council | Composition comprising phosphodiesterase inhibitors for inducing cervical ripening |
US20050169986A1 (en) | 2002-02-28 | 2005-08-04 | Wei Tian | Fast disintegrating tablets |
WO2004000197A2 (en) | 2002-06-21 | 2003-12-31 | Biovail Laboratories Inc. | Quick dissolve compositions and tablets based thereon |
US20060115528A1 (en) | 2002-06-21 | 2006-06-01 | Vesna Skulj | Rapidly disintegrating tablet |
US20060228409A1 (en) | 2003-03-28 | 2006-10-12 | Kyowa Hakko Kogyo Co., Ltd. | Scored tablet |
WO2006125450A1 (en) | 2005-05-26 | 2006-11-30 | Atef Mohammed Mostafa Darwish | Rectal and vaginal suppositories containing misoprostol |
WO2006133048A2 (en) | 2005-06-03 | 2006-12-14 | Duramed Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same |
US20080312168A1 (en) * | 2005-07-22 | 2008-12-18 | Rubicon Research Pvt. Ltd | Novel Dispersible Tablet Composition |
WO2007035954A2 (en) | 2005-09-23 | 2007-03-29 | Duramed Pharmaceuticals, Inc. | Vaginal tablets comprising misoprostol and methods of making and using the same |
US20070071814A1 (en) | 2005-09-23 | 2007-03-29 | Ahmed Salah U | Vaginal tablets comprising misoprostol and methods of making and using the same |
US8148560B2 (en) | 2005-09-23 | 2012-04-03 | Teva Women's Health, Inc. | Vaginal tablets comprising misoprostol and methods of making and using the same |
CN1939308A (en) | 2005-09-28 | 2007-04-04 | 应圣俊 | Misoalprostacol suppository |
EP1987820A1 (en) | 2007-05-04 | 2008-11-05 | Christian Fiala, Ph. D. | Slow release misoprostol for obstetric and/or gynaecological applications |
US20100297031A1 (en) | 2007-10-01 | 2010-11-25 | Laboratorios Lesvi, S.L. | Orodispersible tablets |
WO2009043844A2 (en) | 2007-10-01 | 2009-04-09 | Laboratorios Lesvi, S.L. | Orodispersible tablets |
WO2009154810A2 (en) | 2008-02-25 | 2009-12-23 | Dr. Reddy's Laboratories Ltd. | Delivery systems for multiple active agents |
WO2010036878A1 (en) | 2008-09-26 | 2010-04-01 | The Trustees Of Columbia University In The City Of New York | Use of trpv1 receptor agonists in cervical pain and labor |
US20120077888A1 (en) | 2009-03-26 | 2012-03-29 | Royal College Of Surgeons In Ireland | Orodispersible tablets |
WO2010120345A1 (en) | 2009-04-13 | 2010-10-21 | Nair Madhavan G | Metabolically inert antifolates: new indications and formulations |
US20100260825A1 (en) | 2009-04-13 | 2010-10-14 | Nair Madhavan G | Antifolates for the treatment of cardiovascular, inflammatory, neoplastic, autoimmune and related diseases in sublingual dosage units, film strips, or skin patches |
RU2394814C1 (en) | 2009-05-22 | 2010-07-20 | Учреждение Российской академии наук Институт органической химии Уфимского научного центра РАН | Ethyl ether (±)-11,15-dideoxy-16-methyl-16-hydroxyprostaglandin e1 agent which exhibits uterotonic activity |
WO2011156812A2 (en) | 2010-06-11 | 2011-12-15 | Controlled Therapeutics (Scotland) Ltd. | Intravaginal administration of misoprostol |
CN102302443A (en) | 2011-09-21 | 2012-01-04 | 天津市聚星康华医药科技有限公司 | Misoprostol vaginal sustained-release suppository and preparation method thereof |
CN102697746A (en) | 2012-06-11 | 2012-10-03 | 广州朗圣药业有限公司 | Rapid melting misoprostol vaginal composition as well as preparation method and application of same |
EP2689781A1 (en) | 2012-07-26 | 2014-01-29 | Ferring B.V. | Misoprostol composition |
EP2689802A1 (en) | 2012-07-26 | 2014-01-29 | Ferring B.V. | Misoprostol formulation |
WO2014016390A1 (en) | 2012-07-26 | 2014-01-30 | Ferring B.V. | Misoprostol formulation |
WO2014016394A1 (en) | 2012-07-26 | 2014-01-30 | Ferring B.V. | Misprostol composition |
CN102872024A (en) | 2012-09-28 | 2013-01-16 | 天津市聚星康华医药科技有限公司 | Misoprostol medicine combination used in mouths |
CN103040842A (en) | 2012-12-08 | 2013-04-17 | 杭州圣诺医学科技有限公司 | Prostaglandin pharmaceutical composition and prostaglandin medicament suppository prepared by the prostaglandin pharmaceutical composition |
CN103340837A (en) | 2013-07-08 | 2013-10-09 | 天津市聚星康华医药科技有限公司 | Misoprostol vaginal effervescent tablets and preparation method thereof |
Non-Patent Citations (108)
Title |
---|
Ac-Di-Sol-DuPont-Danisco, 2017, Retrieved from internet <www.danisco.com/pharmaceuticals/pharmaceutical-products/ac-di-sol/ > (2 pages). |
Aggarwal, N. et al., "Use of Misoprostol for Control of Post-Partum Haemorrhage in a Case of Aplastic Anaemia", Bull PGI, (2005), 39, pp. 121-122. |
Alfirevic et al. "Oral misoprostol for induction of labour (Review)," The Cochrane Library, Issue 2, 78 pages, (2006). |
Alfirevic et al. "Oral misoprostol for induction of labour (Review)", The Cochrane Library 2014, Issue 6. |
Amaral et al. "Effect of Hydroxypropyl Methylcellulose and Hydrogenated Castor Oil on Naproxen Release From Sustained-Release Tablets," AAPS PharmSciTech, vol. 2, No. 2, pp. 1-8 (2001). |
American Univ. (Clinical Trails.gov, Sublingual versus Vaginal Misoprostol for Labor Induction at Term, sponsored by American University of Beirut Medical Center (last updated Jul. 12, 2012), [Retrieved from internet <URL: https://clinicaltrials.govict2/show/NCT00140114?term=misoprostol+and+labor+and+sublingual&rank=3 >], 6 pages). |
Amin et al. "Superdisintegrants an economical alternative," Pharma Focus Asia, 3 pages, (2006) www.pharmafocusasia.com/manufacturing/superdisintegrants.htm. |
Asherkaci, H.M. et al., "Misoprostol usefulness on Post Partum Hemorrhage (PPH) among high risk mothers", Jamahiriya Medical Journal, (2010), 10, pp. 213-215. |
Ashland, Inc., Polyplasdone crospovidone superdisintegrants—Product Overview, Ashland (2013) www.ashland.com/products/polyplasdone-crospovidone. |
Astle et al. "Expression and regulation of prostaglandin E synthase isoforms in human myometrium with labour," Molecular Human Reproduction, vol. 13, No. 1, pp. 69-75 (2007). |
Bagnasco et al. "Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings," Journal of Allergy and Clinical Immunology, vol. 100, No. 1, pp. 122-129 (1997). |
Bala et al. "Polymers in fast disintegrating tablets—a review," Asian Journal of Pharmaceutical and Clinical Research, vol. 5, No. 2, pp. 8-14 (2012). |
Bauer "Misoprostol Preclinical Pharmacology," Digestive Diseases and Science, vol. 30, No. 11, pp. 118S-125S (1985). |
Bennett et al. "A Masked Randomized Comparison of Oral and Vaginal Administration of Misoprostol for Labor Induction," Obstetics and Gynecology, vol. 92, No. 4, Part 1, pp. 481-486 (1998). |
Cabero Roura, L. et al., "Post-partum haemorrhage: Diagnosis, prevention and management", The Journal of Maternal-Fetal and Neonatal Medicine, May 2009, 22(S2), pp. 38-45. |
Camarco et al. "Selecting Superdisintegrants for Orally Disintegrating Tablet Formulations," Pharmaceutical Technology, vol. 34, pp. 28-37 (2006) www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=378398. |
Carbonell I Esteve, J.L., "Active management of the third phase of labour plus 400 μg of sublingual misoprostol and 200 μg of rectal misoprostol versus active management only in the prevention of post-partum haemorhage. A randomised clinical trial", Porg Obstet Gnecol, (2009); 52(10), pp. 543-551. |
Casey, F. et al., "A randomized double-blinded comparison of same-day mifepristone and misoprostol with misoprostol only for cervical preparation in second-trimester surgical abortion", Abstracts/Contraception, (2014), 90, pp. 292-297. |
Castaneda et al. "Misoprostol dose selection in a controlled-release vaginal insert for induction of labor in nulliparous women," American Journal of Obstetrics and Gynecology, vol. 193, pp. 1071-1075 (2005). |
Cecatti et al. "Effectiveness and safety of a new vaginal misoprostol product specifically labeled for cervical ripening and labor induction," Acta Obstetricia et Gynecologica, vol. 85, pp. 706-711 (2006). |
Chaudhuri P., et al., "Rectally administrated misoprostol as an alternative to intravenous oxytocin infusion for preventing post-partum hemorrhage after cesarean delivery", J. Obstet. Gynaecol. Res., Sep. 2014, vol. 40, No. 9, pp. 2023-2030. |
Cheng et al. "Titrated oral compared with vaginal misoprostol for labor induction: a randomized controlled trial.", Obstet Gynecol. Jan. 2008;111(1):119-25. |
Choksuchat "Clinical Use of Misoprostol in Nonpregnant Women: Review Article," The Journal of Minimally Invasive Gynecology, vol. 17, No. 4, pp. 449-455 (2010). |
Cytotec—FDA prescribing information, side effects and uses, 2017, [Retrieved from internet <www.drugs.com/pro/cytotec.html > (16 pages). |
Danielsson et al. "Comparison Between Oral and Vaginal Administration of Misoprostol on Uterine Contractility," Obstetrics & Gynecology, vol. 93, No. 2, pp. 275-280 (1999). |
Desai et al. "Functionality of Disintegrants and Their Mixtures in Enabling Fast Disintegration of Tablets by a Quality by Design Approach," American Association of Pharmaceutical Scientists (APPS), vol. 15, No. 5, 12 pages (2014). |
Desai et al. "Understanding Disintegrant Action by Visualization," Journal of Pharmaceutical Sciences, vol. 101, No. 6, pp. 2155-2164 (2012). |
Ding et al. "Low dose intravaginal misoprostol for induction of labor at term," International Journal of Gynecology and Obestetrics, vol. 90, pp. 72-73 (2005). |
Disintegration Test for Suppositories and Vaginal Tablets, Appendix X B, Section II, Chinese Pharmacopoeia (2005). |
Divate et al. "Fast Disintegrating tablets—an emerging trend," International Journal of Pharmaceuticals Sciences Review and Research, vol. 6, No. 2, pp. 18-22 (2011). |
Dressman et al. "Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms," Pharmaceutical Research, vol. 15, No. 1, pp. 11-22 (1998). |
Eikelder et al. "Induction of labour with a Foley catheter or oral misoprostol at term: the PROBAAT-II study, a multicentre randomised controlled trial.", BMC Pregnancy Childbirth. Mar. 19, 2013;13:67. |
Elhassan et al. "Cervical ripening and labor induction with 25 μg vs. 50 μg of intravaginal misoprostol," International Journal of Gynecology & Obstetrics, vol. 90, pp. 234-235 (2005). |
Elhassan et al., "Sublingual compared with oral and vaginal misoprostol for labor induction", Int J Gynecology & Obstetrics, (Jun. 2007) 97(2):153-4 (3 pages with cover) (Year 2007). |
Elhassan, E.M., et al., "Misoprostol vs. oxytocin for induction of labor", International Journal of Gynecology and Obstetrics (2005) 91, 254-255. |
Elhassan, M., et al., "Intravaginal misoprostol vs. dinoprostone as cervical ripening and labor-inducing agents", International Journal of Gynecology and Obstetrics 85 (2004) 285-286. |
European Pharmacopoeia (8th Edition), 2014, chapters: 2.9.3. Dissolution Test for Solid Dosage Forms, pp. 288-295 (8 pages) (2012). |
European Pharmacopoeia (8th Edition), chapter: 2.9.1. Disintegration of Tablets and Capsules, pp. 285-287 (3 pages) (2011). |
European Pharmacopoeia (8th Edition), chapter: 2.9.43 Apparent Dissolution, pp. 361-362 (2 pages) (2008). |
European Pharmacopoeia (8th Edition), chapter: Maize Starch, pp. 2684 (1 page) (2014). |
European Pharmacopoeia (8th Edition), chapter: Oromucosal Preparations, pp. 793-796 (4 pages) (2014). |
European Pharmacopoeia (8th Edition), chapter: Pea Starch, pp. 3799 (1 page) (2014). |
European Pharmacopoeia (8th Edition), chapter: Potato Starch, pp. 3078 (1 page) (2014). |
European Pharmacopoeia (8th Edition), chapter: Rice Starch, pp. 3163 (1 page) (2014). |
European Pharmacopoeia (8th Edition), chapter: Wheat Starch, pp. 3563 (1 page) (2014). |
Ewert et al. "Controlled-Release Misoprostol Vaginal Insert in Parous Women for Labor Induction: A Randomized Controlled Trial," Obstetrics & Gynecology, vol. 108, No. 5, pp. 1130-1137 (2006). |
Feitosa et al. "Sublingual vs. vaginal misoprostol for induction of labor," International Journal of Gynecology & Obstetrics, vol. 94, pp. 91-95 (2006). |
Frokjaer et al. "Protein Drug Stability: A Formulation Challenge," Nature Reviews, vol. 4, pp. 298-306 (2005). |
Ghidini et al. "Randomized controlled trial of 50 and 100 mcg of misoprostol for induction of labor at term," Archives of Gynecology and Obstetrics, vol. 265, pp. 128-130 (2001). |
Gopinath et al. "A Brief Review on Disintegrants", Journal of Chemical and Pharmaceutical sciences, vol. 5, Issue 3, pp. 105-112 (2012). |
Gupta et al. "Comparative evaluation of 25 μg and 50 μg of intravaginal misoprostol for induction of labor," The Journal of Obstetrics and Gynecology of India, vol. 60, No. 1, pp. 51-54 (2010). |
Habib et al. "Fast-Dissolve Drug Delivery Systems," Critical Reviews in Therapeutic Drug Carrier Systems, vol. 17, No. 1, pp. 61-72 (2000). |
Has et al. "Comparison of 25 μg and 50 μg Vaginally Administered Misoprostol for Preinduction of Cervical Ripening and Labor Induction," Gynecologic and Obstetric Investigation, vol. 53, pp. 16-21 (2002). |
Hashima-E-Nasreen, "Oral misoprostol for preventing postpartum haemorrhage in home births in rural Bangladesh: how effective is it?", Global Health Action, (2011), 4:1, 7017, 11 pgs., DOI: 10.3402/gha.v4i0.7017. |
Häusler et al. "Comparison of native starches as tablet disintegrants," Roquette Pharma, 2 pages (2009) www.roquette-pharma.com/white-paper/starch-excipient-tablet-disintegrant-pea-starch-filler-binder/. |
Hofmeyr et al. "Vaginal misoprostol for cervical ripening and induction of labour (Review)," The Cochrane Library, Issue 1, 315 pages, (2003). |
Komala et al. "Comparative Study of Oral and Vaginal Misoprostol for Induction of Labour, Maternal and Foetal Outcome," Journal of Clinical and Diagnostic Research, vol. 7, No. 12, pp. 2866-2869 (2013). |
Krause et al. "Off-label use of misoprostol for labor induction: a nation-wide survey in Switzerland", European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 151, pp. 324-328 (2011). |
Kumar et al. "Fundamental Aspects of Superdisintegrants: A Concise Review," Journal of Global Pharma Technology, vol. 4, No. 02, pp. 1-12 (2012). |
Kundodyiwa et al. "Low-dose oral misoprostol for induction of labor: a systematic review," Obstetrics & Gynecology, vol. 113, No. 2, Part 1, pp. 374-383 (2009). |
Loto et al. "Comparative study of the outcome of induction of labor using 25 μg and 50 μg of vaginal misoprostol," The Journal of Maternal-Fetal & Neonatal Medicine, vol. 25, No. 11, pp. 2359-2362 (2012). |
Majeed, T. et al., "Comparison of Side Effects and Complications of Intravaginal Misoprostol with Extra-Amniotic Prostaglandin F2 Alpha for Termination of Second Trimester Pregnancy", Med. Forum, Dec. 2010, vol. 21, No. 12, 4 pgs. |
Mangal et al. "Superdisintegrants: An updated review," International Journal of Pharmacy and Pharmaceutical Science Research, vol. 2, No. 2, pp. 26-35 (2012). |
Medterms (Definition of Prostaglandin, MedicineNet (2014) [Retrieved from internet <URL: http://www.medterms.com/script/main/artasp?articlekey=16461&pf=2 >1) (1 page). |
Merck (Misoprostol, Merck Index Online (2013), 1 page). |
Meydanli et al. "Labor induction post-term with 25 micrograms vs. 50 micrograms of intravaginal misoprostol," International Journal of Gynecology & Obstetrics, vol. 81, pp. 249-255 (2003). |
Miller et al. "Pharmaceutical tablet lubrication," International Journal of Pharmaceutics, vol. 41, pp. 1-19 (1988). |
Mohanachandran et al. "Superdisintegrants: an overview," International Journal of Pharmaceutical Sciences Review and Research, vol. 6, No. 1, pp. 105-109 (2011). |
Nagar, P. et al., "Orally disintegrating tablets : formulation, preparation techniques and evaluation", Journal of Applied Pharmaceutical Sciences 01 (04); 2011: 35-45. |
Okonofua, F.E., "Assessment of sublingual misoprostol as first-line treatment for primary post-partum hemorrhage: Results of a multicenter trial", J. Obstet. Gynaecol, Res., Mar. 2014, vol. 40, No. 3, pp. 718-722. |
Paisarntantiwong et al. "A comparison between single dose of 50 microg oral misoprostol and 25 microg vaginal misoprostol for labor induction", Journal of the Medical Association of Thailand, vol. 88, suppl. 2 pp. S56-S62 (2005). |
Panigrahi et al. "Effect of Combination of Superdisintegrants on Fast Dissolving Tablet of Gliclazide," WebmedCentral (Pharmaceutical Sciences), vol. 3, No. 4, pp. 1-16 (2012). |
Parveen et al. "Comparison of sublingual, vaginal, and oral misoprostol in cervical ripening for first trimester abortion," Indian Journal of Pharmacology, vol. 43, No. 2, pp. 172-175 (2011). |
Patra et al. "In Vitro Evaluation of Domperidone Mouth Dissolving Tablets," Indian Journal of Pharmaceutical Sciences, vol. 72, No. 6, pp. 822-825 (2010). |
PDR (Misoprostol tablet, PDR3D, Apotheca Inc. (2010), 12 pages). |
Pfizer (Safety Data Sheet-Misoprostol tablets, (Rev. Oct. 27, 2014), [Retrieved from internet <pfizer.com/system/files/products/material_safety_data/Misoprostol_Tablets_27-Oct-2014.pdf (Year: 2014). |
Pharmacia, Cytotec 200 microgram Tablets (Misoprostol), Package leaflet: Information for the user, Feb. 2010. |
Piriyaprasarth et al. "Effect of source variation on drug release from HPMC tablets: Linear regression modeling for prediction of drug release," International Journal of Pharmaceutics, vol. 411, pp. 36-42 (2011). |
Priyanka et al. "A Review Article on: Superdisintegrants", International Journal of Drug Research and Technology, 2013, vol. 3 (4), 76-87, ISSN 2277-1506. |
Rowe et al., Starch, Handbook of Pharmaceutical Excipients (7th Edition), pp. 784, Pharmaceutical Press (2012). |
Salsa et al. "Oral Controlled-Release Dosage Forms. I. Cellulose Ether Polymers in Hydrophilic Matrices," Drug Development and Industrial Pharmacy, vol. 23, No. 9, pp. 929-938 (1997). |
Sanchez-Ramos et al. "Labor Induction With 25 μg Versus 50 μg Intravaginal Misoprostol: A Systematic Review," The American College of Obstetricians and Gynecologists, vol. 99, No. 1, pp. 145-151 (2002). |
Santos et al. "Tablet Compression," Pharmaceutical Manufacturing Handbook: Production and Processes, pp. 1133-1163, Chap. 6.6 (2008). |
Schmaljohann "Thermo- and pH-responsive polymers in drug delivery," Advanced Drug Delivery Reviews, vol. 58, pp. 1655-1670 (2006). |
Shetty et al. "A comparison of oral and vaginal misoprostol tablets in induction of labour at term," British Journal of Obstetrics and Gynaecology, vol. 108, pp. 238-243 (2001). |
Shetty, A. et al., "Sublingual misoprostol for the induction of labor at term", American Journal of Obstetrics and Gynecology, vol. 186, No. 1, Jan. 2002, p. 72-76. |
Shihora et al., Superdisintegrants, Utility in Dosage Forms: A Quick Review, Journal of Pharmaceutical Science and Bioscientific Research (JPSBR), Nov.-Dec. 2011; 1 (3): 148-153. |
Siddiqui et al. "A Short Review on "A Novel Approach in Oral Fast Dissolving Drug Delivery Systems and Their Patents"," Advances in Biological Research, vol. 5, No. 6, pp. 291-303 (2011). |
Surbek "Misoprostol for labor induction in term pregnancy", Eur Clinics Obstet Gynaccol (2007) 3:25-29. |
Suryadevara V et al. "Studies on jackfruit seed starch as a novel natural superdisintegrant for the design and evaluation of irbesartan fast dissolving tablets.", Integr Med Res. Sep. 2017;6(3):280-291. doi: 10.1016/j.imr.2017.04.001. Epub May 26, 2017. |
Szczesny et al. "Pre-induction cervical ripening with 25 μg and 50 μg vaginal misoprostol in 181 nulliparous parturients," The Journal of Maternal-Fetal & Neonatal Medicine, vol. 22, No. 3, pp. 265-268 (2009). |
Tang et al. "Misoprostol: Pharmacokinetic profiles, effects on the uterus and side-effects", International Journal of Gynecology & Obstetrics, pp. 160-167 (2007). |
Tang et al. "Pharmacokinetics of different routes of administration of misoprostol," Human Reproduction, vol. 17, No. 2, pp. 332-336 (2002). |
Tang et al., "Pilot study on the due of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation", Human Reproduction, 2002, vol. 17, No. 7, pp. 1738-1740. |
Tewatia, R., et al., "Sublingual misoprostol versus intravenous oxytocin in prevention of post-partum hemorrhage", Arch. Gynecol. Obstet., Sep. 18, 2013, DOI 10.1007/s00404-013-3026-2. |
Torres-Lugo et al. "Molecular Design and in Vitro Studies of Novel pH-Sensitive Hydrogels for the Oral Delivery of Calcitonin," Macromolecules, vol. 32, pp. 6646-6651 (1999). |
U.S. Food and Drug Administration, "Misoprostol (marketed as Cytotec) Information," U.S. Department of Health & Human Services, 2pages, May 2009, www.fda.gov. |
United States Pharmacopeia (2008), <701> Disintegration, p. 1, Apparatus, [Retrieved from internet <URL: http://www.usp.org/sites/default/files/usp_pdf/EN/USPNF/generalChapter701.pdf >], 3 pages. |
Villano et al. "A dose-finding study of oral misoprostol for labor augmentation," American Journal of Obstetrics and Gynecology, vol. 204 pp. 560.e1-560.e5 (2011). |
Vivek et al. "Fast Dissolving Tablets: An Overview," International Journal of Pharmaceutical Sciences Review and Research, vol. 12, No. 1, pp. 35-41 (2012). |
Wang (Zhonghua Fu Chan Ke Za Zhi, 1998, vol. 33, pp. 469-471) (Year: 1998). * |
Wang et al. "Lubrication in tablet formulation," European Journal of Pharmaceutics and Biopharmaceutics, vol. 75, pp. 1-15 (2010). |
Watkinson et al., Misoprostol in peptic ulcer disease, Prostglandins (1987) 33 Suppl.: 78-92, [Retrieved from internet <URL: http://www.ncbi.nlm.nih.gov/pubmed/3122278 >1; Abs. only (2 pages). |
Wing et al. "A comparison of orally administered misoprostol with vaginally administered misoprostol for cervical ripening and labor induction", Am J Obstet Gynecol. May 1999;180(5):1155-60. |
Winikoff, B., et al., "Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority trial", Lancet, (2010), vol. 375, pp. 210-216c. |
World Health Organization, WHO recommendations for induction of labour, 39 pages, (2011) www.who.int/iris/handle/10665/44531#sthash.6H0dFDkA.dpuf. |
www.urmc.rochesteredu/encyclopedia/content.aspx?ContentTypeID=90&ContentID=P02021; Stomach and Duodenal Ulcers (Peptic Ulcers) in Children; retrieved on Dec. 18, 2015. |
Zulfiker, AH. et al., "Formulation development using maize starch & avicel PH101 as disintegrating agents and their effect on physical characteristics & in vitro release profile", International Journal of Pharmaceutical Sciences and Research, 2011; vol. 2(8): 2136-2141. |
Also Published As
Publication number | Publication date |
---|---|
WO2016004960A3 (en) | 2016-03-17 |
MX2017000399A (en) | 2017-08-10 |
RU2017104233A (en) | 2018-08-13 |
RU2017104233A3 (en) | 2018-12-18 |
JP6921894B2 (en) | 2021-08-18 |
JP2017520628A (en) | 2017-07-27 |
AU2015287186B2 (en) | 2018-05-31 |
BR112017000529A2 (en) | 2017-11-14 |
WO2016004960A2 (en) | 2016-01-14 |
US20210322356A1 (en) | 2021-10-21 |
NZ727876A (en) | 2018-05-25 |
US20220347145A1 (en) | 2022-11-03 |
CA2954086A1 (en) | 2016-01-14 |
CA2954086C (en) | 2020-03-31 |
TN2017000003A1 (en) | 2018-07-04 |
EP3166597A2 (en) | 2017-05-17 |
US11406615B2 (en) | 2022-08-09 |
EA201692536A1 (en) | 2017-06-30 |
EA039069B1 (en) | 2021-11-30 |
JP6532529B2 (en) | 2019-06-19 |
JP2019147831A (en) | 2019-09-05 |
AU2015287186A1 (en) | 2017-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1732522B1 (en) | Gastric retention system | |
RU2479306C2 (en) | Pharmaceutical composition containing tetrahydrofolic acid | |
CN101005831B (en) | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof | |
US10828258B2 (en) | Directly compressible composition comprising microcrystalline cellulose | |
TW200938210A (en) | Pharmaceutical compositions | |
US20170216213A1 (en) | Directly compressible polyvinyl alcohols | |
US12005041B2 (en) | Misoprostol dispersible tablet | |
US20170281584A1 (en) | Misoprostol Dispersible Tablet | |
JP2018065776A (en) | Pharmaceutical composition particle and orally disintegrable preparation containing the same, and method for producing pharmaceutical composition particle | |
EP2387388A1 (en) | Sprm pharmaceutical compositions methods of treatment using them | |
EP2965750B1 (en) | Misoprostol dispersible tablet | |
JP4842960B2 (en) | Method for producing a compressed solid dosage form well suited for use with low water-soluble drugs and compressed solid dosage form produced thereby | |
US20200214985A1 (en) | Pharmaceutical composition particles, orally disintegrating preparation containing same, and method for producing pharmaceutical composition particles | |
US20090264495A1 (en) | Oral sustained-release pharmaceutical composition of indapamide, production and use thereof | |
CN116322701A (en) | Novel modified release oral contraceptive compositions | |
JP5508311B2 (en) | Method for producing a compressed solid dosage form well suited for use with low water-soluble drugs and compressed solid dosage form produced thereby | |
Ghali | Design, Development and Characterisation of Hydrogel Based Floating Drug Delivery System of a Model Anti Ulcer Drug | |
Ghurghure | Design and development of zidovudine gas powered systems for controlles release using natural and synthetic polymer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: AZANTA DANMARK A/S, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SEKAR, SELVARAJ;BASKAR, ELUMALAI;MALAIARASAN, ARUNACHALAM;AND OTHERS;REEL/FRAME:060664/0788 Effective date: 20170327 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |